Nuveen’s Protalix BioTherapeutics PLX Stock Holding History

Nuveen’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$196K	Hold	90,188	–	–	﹤0.01%	3098
2025 Q4	$162K	Hold	90,188	–	–	﹤0.01%	3178
2025 Q3	$200K	Hold	90,188	–	–	﹤0.01%	3149
2025 Q2	$133K	Buy	+90,188	New	+$185K	﹤0.01%	3227
2024 Q2	–	Sell	-271,795	Closed	-$342K	–	3397
2024 Q1	$342K	Hold	271,795	–	–	﹤0.01%	3074
2023 Q4	$484K	Buy	271,795 +9,714	+4%	+$15.1K	﹤0.01%	3013
2023 Q3	$435K	Hold	262,081	–	–	﹤0.01%	2890
2023 Q2	$524K	Buy	+262,081	New	+$624K	﹤0.01%	2907

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Nuveen's PLX Position: Q1 2026 in Review

Nuveen held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 90,188 shares worth $196K. The position accounts for ﹤0.01% of the portfolio, ranked #3098.

Nuveen first reported a position in PLX in Q2 2023 and has held it in 8 quarters since. The position peaked at $524K in Q2 2023. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Nuveen held 90,188 shares of Protalix BioTherapeutics worth $196K as of Q1 2026.
Nuveen left its Protalix BioTherapeutics share count unchanged in Q1 2026.
Protalix BioTherapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #3098 holding.
Nuveen first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 8 quarters since.
Nuveen's Protalix BioTherapeutics position peaked at $524K in Q2 2023.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.